Twist Bioscience (TWST) 10-Q 9 Feb 21 2021 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Dec. 31, 2020	Feb. 04, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Registrant Name	Twist Bioscience Corporation
Entity Central Index Key	0001581280
Entity Shell Company	false
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Security Exchange Name	NASDAQ
Entity Address, State or Province	CA
Title of 12(b) Security	Common Stock
Trading Symbol	TWST
Entity Common Stock, Shares Outstanding		48,646,513
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-38720
Entity Address, Address Line One	681 Gateway Blvd,
Entity Address, City or Town	South San Francisco,
Entity Address, Postal Zip Code	94080
Entity Tax Identification Number	46-2058888
City Area Code	800
Local Phone Number	719-0671

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Sep. 30, 2020
Current assets:
Cash and cash equivalents	$ 348,789	$ 93,667
Short-term investments	238,496	196,335
Accounts receivable, net	25,492	26,376
Inventories	13,409	12,289
Prepaid expenses and other current assets	8,242	6,203
Total current assets	634,428	334,870
Property and equipment, net	27,153	25,466
Operating lease right-of-use assets	32,330	33,699
Goodwill	1,138	1,138
Intangible assets, net	256	307
Restricted cash, non-current	1,530	579
Other non-current assets	2,735	2,823
Total assets	699,570	398,882
Current liabilities:
Accounts payable	8,932	4,830
Accrued expenses	3,510	3,901
Accrued compensation	11,577	14,945
Current portion of operating lease liability	6,444	6,409
Current portion of long-term debt	3,333	3,333
Other current liabilities	3,306	2,611
Total current liabilities	37,102	36,029
Operating lease liability, net of current portion	23,681	24,837
Long-term debt, net of current portion	625	1,403
Other non-current liabilities	210	351
Total liabilities	61,618	62,620
Commitments and contingencies (Note 6)
Stockholders' equity
Common stock, $0.00001 par value—100,000 and 100,000 shares authorized at December 31, 2020 and September 30, 2020, respectively; 48,616 and 45,083 shares issued and outstanding at December 31, 2020 and September 30, 2020, respectively
Additional paid-in capital	1,129,165	794,630
Accumulated other comprehensive income	142	87
Accumulated deficit	(491,355)	(458,455)
Total stockholders' equity	637,952	336,262
Total liabilities and stockholders' equity	$ 699,570	$ 398,882

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Sep. 30, 2020
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, share authorized	100,000,000	100,000,000
Common stock, share issued	48,616,000	45,083,000
Common stock, share outstanding	48,616,000	45,083,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statements of Operations and Comprehensive Loss
Revenues	$ 28,161	$ 17,164
Operating expenses:
Cost of revenues	18,162	13,792
Research and development	14,000	10,297
Selling, general and administrative	28,792	26,405
Litigation settlement	0	22,500
Total operating expenses	60,954	72,994
Loss from operations	(32,793)	(55,830)
Interest income	134	564
Interest expense	(118)	(248)
Other income (expense), net	(77)	(87)
Loss before income taxes	(32,854)	(55,601)
Provision for income taxes	(46)	(37)
Net loss attributable to common stockholders	(32,900)	(55,638)
Other comprehensive loss:
Change in unrealized income/(loss) on investments	(8)	16
Foreign currency translation adjustment	63	(7)
Comprehensive loss	$ (32,845)	$ (55,629)
Net loss per share attributable to common stockholders—basic and diluted	$ (0.72)	$ (1.69)
Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted	46,000	32,976

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated deficit [Member]
Beginning Balance at Sep. 30, 2019	$ 152,082		$ 470,425	$ 181	$ (318,524)
Beginning Balance , shares at Sep. 30, 2019		32,873
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses	2,024		2,024
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses, shares		97
Vesting of restricted stock units, shares		85
Exercise of stock options	1,715		1,715
Exercise of stock options , shares		242
Repurchases of early exercised stock options, shares		(1)
Repurchases of common stock for income tax withholding	(808)		(808)
Repurchases of common stock for income tax withholding , shares		(35)
Stock-based compensation	3,697		3,697
Other comprehensive income	9			9
Net loss	(55,638)				(55,638)
Ending Balance at Dec. 31, 2019	103,081		477,053	190	(374,162)
Ending Balance , shares at Dec. 31, 2019		33,261
Beginning Balance at Sep. 30, 2020	336,262		794,630	87	(458,455)
Beginning Balance , shares at Sep. 30, 2020		45,083
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses	323,851		323,851
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses, shares		3,136
Vesting of restricted stock units, shares		54
Exercise of stock options	6,072		6,072
Exercise of stock options , shares		345
Net exercise of stock warrants , shares		22
Repurchases of common stock for income tax withholding	(2,410)		(2,410)
Repurchases of common stock for income tax withholding , shares		(24)
Stock-based compensation	7,022		7,022
Other comprehensive income	55			55
Net loss	(32,900)				(32,900)
Ending Balance at Dec. 31, 2020	$ 637,952		$ 1,129,165	$ 142	$ (491,355)
Ending Balance , shares at Dec. 31, 2020		48,616

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Common Stock [Member]
Net of underwriting discounts, commissions and offering expenses	$ 21,149	$ 276

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net loss	$ (32,900)	$ (55,638)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	2,111	1,505
Loss on disposal of property and equipment	2
Non-cash lease expense	248	236
Stock-based compensation	7,022	3,697
Discount accretion on investment securities	122	(150)
Non-cash interest expense	25	46
Amortization of debt discount	30	56
Changes in assets and liabilities:
Accounts receivable, net	884	(950)
Inventories	(1,122)	(86)
Prepaid expenses and other current assets	(2,043)	(2,917)
Other non-current assets	59	62
Accounts payable	3,459	(556)
Accrued expenses	(149)	(1,279)
Accrued Compensation	(3,357)	(1,629)
Accrued litigation settlement		22,500
Other liabilities	677	189
Net cash used in operating activities	(24,932)	(34,914)
Cash flows from investing activities
Purchases of property and equipment	(3,629)	(2,058)
Purchases of investments	(74,292)	(6,537)
Proceeds from maturity of investments	32,000	21,000
Net cash (used in) / provided by investing activities	(45,921)	12,405
Cash flows from financing activities
Proceeds from exercise of stock options	6,084	1,674
Proceeds from public offering, net of underwriting discounts and commissions and offering expenses	324,080	2,024
Repayments of long-term debt	(833)	(833)
Repurchases of common stock for income tax withholding	(2,410)	(808)
Net cash provided by financing activities	326,921	2,057
Effect of exchange rates on cash, cash equivalents and restricted cash	5	9
Net increase (decrease) in cash, cash equivalents, and restricted cash	256,073	(20,443)
Cash, cash equivalents, and restricted cash at beginning of period	94,246	47,398
Cash, cash equivalents, and restricted cash at end of period	350,319	26,955
Supplemental disclosure of cash flow information
Interest paid	61	146
Income taxes paid, net of refunds	81	44
Non-cash investing and financing activities
Property and equipment additions included in accounts payable and accrued expenses	1,515	66
Operating lease right-of-use assets obtained in exchange for operating lease liabilities		$ 2,833
Deferred offering costs included in accounts payable and accrued expenses	$ 229

The company

The company	3 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	1. The Company Twist Bioscience Corporation (the Company) was incorporated in the state of Delaware on February 4, 2013. The Company is a synthetic biology and genomics company that has developed a disruptive DNA synthesis platform. DNA is used in many applications across different industries: industrial chemicals, academic, healthcare and agriculture. The Company’s fiscal year ends on September 30. The Company has generated net losses in all periods since its inception. As of December 31, 2020, the Company had an accumulated deficit of $491.4 million and has not generated positive cash flows from operations since inception. Losses are expected to continue as the Company continues to invest in product development, manufacturing, and sales and marketing. The Company has raised multiple rounds of debt and equity financing since its inception. In October 2018, the Company completed an initial public offering (IPO) of its common stock which raised proceeds of $69.6 million, after deducting underwriting discounts and commissions and offering expenses. In May 2019, the Company completed an underwritten public offering of its common stock with proceeds of $84.3 million, after deducting underwriting discounts and commissions and offering expenses. In December 2019 and January 2020, the Company entered into a sales agreement with Cowen and Company, LLC for an at-the-market offering (ATM) to sell its common stock with net proceeds of $48.0 million, after deducting underwriting discounts and commissions and offering expenses. In February 2020, the Company completed an underwritten public offering of its common stock with net proceeds of $140.2 If the Company requires but is unable to obtain additional funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or ability to achieve its intended expansion objectives or In March 2020, the World Health Organization declared the COVID-19 outbreak to be a pandemic. During the three months ended December 31, 2020, financial results of the Company were not significantly affected by the COVID-19 outbreak. The Company has considered all information available as of the date of issuance of these financial statements and the Company is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. The extent to which the COVID-19 outbreak affects the Company’s future financial results and operations will depend on future developments which continue to evolve are difficult to predict, mutations in SARS-CoV-2 virus, which may make it more contagious,

Summary of significant accounti

Summary of significant accounting policies	3 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of significant accounting policies	2. Summary of significant accounting policies Basis of presentation and use of estimates The accompanying unaudited condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K for the fiscal year ended September 30, 2020 (the Annual Report on Form 10-K) filed with the Securities and Exchange Commission on November 27, 2020. The condensed consolidated financial statements are unaudited and have been prepared on a basis consistent with that used to prepare the audited annual consolidated financial statements and include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. The condensed consolidated balance sheet at September 30, 2020 is derived from audited consolidated financial statements but does not include all disclosures required by GAAP. The operating results for the three months ended December 31, 2020 are not necessarily indicative of the results expected for the full year ending September 30, 2021 or any interim period. The presentation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company’s unaudited condensed consolidated financial statements include its wholly owned subsidiaries. All intercompany balances and accounts are eliminated in consolidation. The following table provides a reconciliation of the Company’s cash and cash equivalents and non-current portion of restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total cash, cash equivalents and restricted cash shown in the Company’s condensed consolidated statements of cash flows: (in thousands) December 2020 September 30, 2020 Cash and cash equivalents $ 348,789 $ 93,667 Restricted cash, non-current 1,530 579 Total cash, cash equivalents and restricted cash $ 350,319 $ 94,246 Significant accounting policies There have been no material changes in the accounting policies from those disclosed in the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K. Recent accounting pronouncements Recent adopted accounting pronouncements – Leases In February 2016, the Financial Accounting Standards Board (FASB) issued new lease accounting guidance in Accounting Standard Update (ASU) 2016-02, Leases, and in July 2018 issued ASU 2018-10, Codification Improvements to Topic 842, Leases, and ASU 2018-11, Leases (Topic 842): Targeted Improvements (the foregoing ASUs collectively referred to as “Topic 842”). Under the new guidance, lessees are required to recognize for all leases (with the exception of short-term leases) at the commencement date: (1) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and (2) a right-of-use asset, which is an asset that represents the lessee’s right to use or control the use of, a specified asset for the lease term. On October 1, 2019, the Company adopted Topic 842 using the modified retrospective approach. The adoption had a material effect on the condensed consolidated balance sheets but did not have a material effect on the condensed consolidated statements of operations and comprehensive loss. Prior period amounts were not adjusted and continue to be reported in accordance with the previous accounting under ASC 840, Leases. The Company elected the package of practical expedients permitted under the transition guidance which, among other things, allows carrying forward the historical classification of existing leases as of October 1, 2019. As a result of electing the transition guidance as described above, on October 1, 2019, the Company recorded operating lease right-of-use assets of $35.8 million, including the derecognition of deferred rent of $0.1 million and prepaid rent of $1.6 million, with the corresponding lease liabilities totaling $34.3 million. There was no material effect to the Company’s statements of operations and comprehensive loss upon adoption. Under Topic 842, the Company determines if an arrangement is a lease at inception primarily based on the determination of the party responsible for directing the use of an underlying asset within a contract. Operating lease right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of committed lease payments over the lease term. In determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date which includes significant assumptions made including the Company’s estimated credit rating, annual percentage yields from corporate debt financings of companies of similar size and credit rating over a loan term approximating the remaining term of each lease, and government bond yields for terms approximating the remaining term of each lease in countries where the leased assets are located. Certain leases include payments of operating expenses that are dependent and may be revised based on the landlord’s estimate, and these variable payments are therefore excluded from the lease payments used to determine the operating lease right-of-use asset and lease liability. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise any such options. Lease expense is recognized on a straight-line basis over the expected lease term. The Company elected to not apply the recognition requirements of Topic 842 to short-term leases with terms of 12 months or less which do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. For short-term leases, lease payments are recognized as operating expenses on a straight-line basis over the lease term. The Company elected to account for lease and non-lease components as a single lease component. Additional information and disclosures required by Topic 842 are contained in Note 6. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Subtopic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement In November 2018, the FASB is s Recently issued accounting pronouncement not yet adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes Income Taxes The ASU is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years, with early adoption permitted. The Company is currently assessing the impact of adoption on its disclosures.

Fair value measurement

Fair value measurement	3 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair value measurement	3. Fair value measurement The Company assesses the fair value of financial instruments based on the provisions of ASC 820, Fair Value Measurements Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company short-term investments primarily utilize broker quotes in a non-active market for valuation of its short-term investments. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 and September 30, 2020 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value. December 31, 2020 (in thousands) Level 1 Level 2 Level 3 Fair value Assets Cash $ 40,108 $ — $ — $ 40,108 Money market funds 308,681 — — 308,681 Commercial paper — 132,867 — 132,867 U.S. government treasury bills 105,629 — — 105,629 Totals $ 454,418 $ 132,867 $ — $ 587,285 September 30, 2020 (in thousands) Level 1 Level 2 Level 3 Fair value Assets Cash $ 20,254 $ — $ — $ 20,254 Money market funds 73,413 — — 73,413 Commercial paper — 94,840 — 94,840 U.S. government treasury bills 101,495 — — 101,495 Totals $ 195,162 $ 94,840 $ — $ 290,002 As of December 31, 2020, and September 30, 2020, gross unrealized gains and unrealized losses for cash equivalents and short-term investments were not material, and the contractual maturities of all marketable securities were less than one year.

Balance sheet components

Balance sheet components	3 Months Ended
	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Balance sheet components	4. Balance sheet components The Company’s accounts receivable, net balance consists of the following: (in thousands) December 31, 2020 September 30, 2020 Trade Receivables $ 23,639 $ 25,790 Other Receivables 2,260 951 Allowance for Doubtful Accounts (407 ) (365 ) Accounts Receivable, net $ 25,492 $ 26,376 Inventory consist of the following: (in thousands) December 31, 2020 September 30, 2020 Raw Materials $ 9,940 $ 9,237 Work-in-process 1,701 2,021 Finished Goods 1,768 1,031 $ 13,409 $ 12,289

Goodwill and intangible assets

Goodwill and intangible assets	3 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and intangible assets	5. Goodwill and intangible assets There were no changes to the carrying value of goodwill as of December 31, 2020 and September 30, 2020. Total amortization expense related to intangible assets was less than $0.1 million for the three months ended December 31, 2020 and 2019. The intangible assets balances are presented below: December 31, 2020 (in thousands, except for years) Useful lives in years Gross carrying amount Accumulated amortization Net book value Developed Technology 6 $ 1,220 $ (964 ) $ 256 Tradenames & Trademarks 2 20 (20 ) — Total indefinite-lived intangible assets $ 1,240 $ (984 ) $ 256 September 30, 2020 (in thousands, except for years) Useful lives in years Gross carrying amount Accumulated amortization Net book value Developed Technology 6 $ 1,220 $ (913 ) $ 307 Tradenames & Trademarks 2 20 (20 ) — Total indefinite-lived intangible assets $ 1,240 $ (933 ) $ 307

Commitments and contingencies

Commitments and contingencies	3 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	6. Commitments and contingencies Indemnifications In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend the indemnified parties for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. To date, the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require it to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by corporate law. The Company also has directors’ and officers’ insurance. Leases The Company leases certain of its facilities under non-cancellable operating leases expiring at various dates through 2026. The Company is also responsible for utilities, maintenance, insurance, and property taxes under these leases. Certain leases include options to renew or terminate at the Company’s discretion. The lease terms include periods covered by these options if it is reasonably certain the Company will renew or not terminate. The Company’s lease agreements do not contain any material residual value guarantees or restrictive covenants. Supplemental balance sheet information related to the Company’s operating lease as of December 31, 2020, was the following: (in thousands) December 31, 2020 Assets: Operating lease right-of-use-asset $ 32,330 Current liabilities: Current portion of operating lease liabilities $ 6,444 Noncurrent liabilities: Operating lease liabilities, net of current portion $ 23,681 Future minimum lease payments under all non-cancelable operating leases that have commenced (in thousands) Operating leases Years ending September 30: Remainder of 2021 $ 4,850 2022 7,140 2023 6,761 2024 6,392 2025 6,433 Thereafter 4,906 Total minimum lease payments $ 36,482 Less: imputed interest (6,357 ) Total operating lease liabilities $ 30,125 Less: current portion (6,444 ) Operating lease liabilities, net of current portion $ 23,681 Operating lease expense was $1.9 million and $2.0 million for the three months ended December 31, 2020 and 2019 respectively. Cash payments for amounts included in the measurement of operating lease liabilities were $1.7 million and $1.9 million for the three months ended December 31, 2020 and 2019 respectively. As of December 31, 2020, the weighted-average remaining lease term was 5.28 years and the weighted-average discount rate was 6.99%. In December 2020, the Company entered into a 12-year operating lease for a 110,995 - - . The lease commencement is contingent upon assuming control over the facility which is not expected to occur until the landlord completes their portion of the buildout which has not yet commenced as of December 31, 2020. The future minimum lease payments under the agreement are $27.9 million.

Related party transactions

Related party transactions	3 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related party transactions	7. Related party transactions During the three months ended December 31, 2020 and 2020, the Company purchased raw materials from a related party investor in the amount of $1.1 million and $0.7 million, respectively. Payable balances and cash receipts and receivable balances with the related party were immaterial as of December 31, 2020 and September 30, 2020.

Income taxes

Income taxes	3 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income taxes	8. Income taxes In determining quarterly provisions for income taxes, the Company uses the annual estimated effective tax rate applied to the actual year-to-date profit or loss, adjusted for discrete items arising in that quarter. The Company’s annual estimated effective tax rate differs from the U.S. federal statutory rate primarily as a result of state taxes, foreign taxes, and changes in the Company’s valuation allowance against its deferred tax assets. For each of the three months ended December 31, 2020 and 2019, the Company recorded an immaterial provision for income taxes.

Warrants

Warrants	3 Months Ended
	Dec. 31, 2020
Text Block [Abstract]
Warrants	9. Warrants In connection with its long-term debt agreements, the Company issued 18,854 and 7,531 on December 22, 2015 and March 28, 2016, respectively

Common stock

Common stock	3 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Common stock	10. Common stock In December 2019, the Company entered into a sales agreement with Cowen and Company, LLC for an at-the-market offering (ATM) to offer and sell shares of its common stock having an aggregate offering price of up to $50.0 million from time to time. The offering was completed during December 2019 and January 2020. During this period, the Company sold a total of 2,239,680 shares of its common stock at a weighted-average price of $22.32 per share and received total net proceeds of $48.0 million under the ATM, net of estimated underwriting discounts and commissions and offering expenses. In February 2020, the Company completed an underwritten public offering of 4,642,857 shares of its common stock at a price to the public of $28.00 per share, including the full exercise of the underwriters’ option to purchase an additional 696,428 shares of common stock. The Company received total net proceeds from the offering of $140.2 million, net of estimated underwriting discounts and commissions and offering expenses. In June 2020, the Company completed an underwriting public offering of 3,484,848 shares of its common stock at a price to the public of $33.00 per share, including the full exercise of underwriters’ option to purchase an additional 454,545 shares of common stock. The Company received total net proceeds from the offering of $107.4 million, net of estimated underwriting discounts and commissions and offering expenses. In December 2020, the Company completed an underwriting public offering of 3,136,362 shares of its common stock at a price to the public of $110.00 per share, including the full exercise of underwriters’ option to purchase an additional 409,090 shares of common stock. The Company received total net proceeds from the offering of $323.9 million, net of estimated underwriting discounts and commissions and offering expenses.

Stock-based compensation

Stock-based compensation	3 Months Ended
	Dec. 31, 2020
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based compensation	11. Stock-based compensation 2018 Equity Incentive Plan On September 26, 2018, the board of directors adopted the 2018 Equity Incentive Plan (the 2018 Plan) as a successor to the 2013 Stock Plan (the 2013 Plan). The number of shares reserved for issuance under the 2018 Plan upon approval of the plan was 5,856,505 shares of the Company’s common stock. The number of shares reserved for issuance under the 2018 Plan will increase automatically on the first day of each fiscal year, following the fiscal year in which the 2018 Plan became effective, by a number equal to the least of 999,900 shares, 4% of the shares of common stock outstanding at that time, or such number of shares determined by the Company’s board of directors. The common shares issuable under the 2018 Plan were registered pursuant to a registration statement on Form On September 1, 2020, the board of directors approved the implementation of a revised annual equity award program for executive officers and senior level employees to be granted as performance-based stock units (PSUs) under the 2018 Plan. The number of PSUs ultimately earned under these awards is calculated based on the achievement of certain total revenue threshold during the fiscal year ending September 30, 2022. The percentage of PSUs PSUs As of December 31, 2020, the that based on the probability of the performance condition that will be achieved The Company reassesses the probability of the performance condition at each reporting period and adjusts the compensation cost based on the probability assessment. Any shares subject to outstanding awards under the 2013 Equi t t Activity under the equity incentive plans during the three months ended (In thousands, except per share data) Shares available Options outstanding Weighted average Weighted average remaining contractual term (years) Aggregate intrinsic value Outstanding at September 30, 2020 1,034 3,913 $ 24.35 8.1 $ 204,365 Stock options granted (33 ) 33 100.21 Stock options exercised — (348 ) 17.59 Stock options forfeited 29 (29 ) 31.32 Restricted stock units granted (289 ) — — Forfeiture of restricted stock units 9 — — Shares withheld for payment of taxes 24 — — Outstanding at Decem b 774 3,569 $ 24.99 7.9 $ 415,052 Vested or expected to vest 3,569 $ 24.99 7.9 $ 415,052 Vested and exercisable at December 31, 202 0 1,300 $ 14.99 7.0 $ 164,229 Total stock-based compensation expense recognized was as follows: Three months ended December 31, (in thousands) 2020 2019 Cost of revenues $ 487 $ 360 Research and development 2,001 728 Selling, general and administrative 4,534 2,609 Total stock-based compensation $ 7,022 $ 3,697 As of December 31, 2020, there was $38.4 million of total unrecognized compensation cost related to non-vested stock options under the equity incentive plans that are expected to be recognized over a weighted average period of 2.3 years. The weighted-average grant date fair value of stock options granted during the three months ended December 31, 2020 was $63.28 per share. Restricted Stock Units Restricted stock primarily consists of restricted stock unit awards (RSUs) which have been granted to employees. The value of an RSU award is based on the Company’s stock price on the date of grant. The shares underlying the RSU awards are not issued until the RSUs vest. Upon vesting, each RSU converts into one share of the Company’s common stock. Activity with respect to the Company’s RSUs (in thousands, except per share data) Number of Shares Weighted average grant date fair value per share Weighted average remaining contractual term (years) Aggregate Intrinsic Value Outstanding at September 30, 2020 569 $ 32.96 3.2 $ 43,260 Restricted stock units granted 289 100.13 Restricted stock units vested (56 ) 24.86 Restricted stock units forfeited (9 ) 65.63 Outstanding at December 31, 2020 793 $ 57.67 3.3 $ 112,013 Expected to vest at December 31, 2020 793 $ 57.67 3.3 $ 112,013 As of December 31, 2020, there was $43.8 million of total unrecognized compensation cost related to these issuances that is expected to be recognized over a weighted average period of 3.0 years. 2018 Employee Stock Purchase Plan On September 26, 2018, the board of directors adopted the 2018 Employee Stock Purchase Plan (the 2018 ESPP). A total of 275,225 shares of the Company’s common stock have been reserved for issuance under the 2018 ESPP. The number of shares reserved for issuance under the 2018 ESPP will increase (In thousands) Shares available Outstanding at September 30, 2020 179 Additional shares authorized 250 Shares issued during the period — Outstanding at December 31, 2020 429 Subject to any plan limitations, the 2018 ESPP allows eligible service providers (through qualified and non-qualified offerings) to contribute, normally through payroll deductions, up to 15% of their earnings for the purchase of the Company’s common stock at a discounted price per share. The offering periods begin for Unless otherwise determined by the board of directors, the Company’s common stock will be purchased for the accounts of employees participating in the 2018 ESPP at a price per share that is the lesser of 85% of the fair market value of the Company’s common stock on the first trading day of the offering period .

Net loss per share attributable

Net loss per share attributable to common stockholders	3 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Net loss per share attributable to common stockholders	12. Net loss per share attributable to common stockholders The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders: Three months ended December 31, (in thousands, except per share data) 2020 2019 Numerator: Net loss attributable to common stockholders $ (32,900 ) $ (55,638 ) Denominator: Weighted average shares used in computing net loss per share, basic and diluted 46,000 32,976 Net loss per share attributable to common stockholders, basic and diluted $ (0.72 ) $ (1.69 ) The potentially dilutive common shares that were excluded from the calculation of diluted net loss per share because their effect would have been anti- dilutive for the periods presented are as follows: Three months ended December 31, (in thousands) 2020 2019 Shares subject to options to purchase common stock 3,569 4,210 Shares subject to performance-based stock options 37 — Unvested restricted shares of common stock — 14 Unvested restricted stock unit s 793 566 Unvested shares of common stock issued upon early exercise of stock options 13 32 Shares subject to employee stock purchase plan 31 80 Shares subject to warrants to purchase common stock — 26 Total 4,443 4,928

Geographic, product and industr

Geographic, product and industry information	3 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Geographic, product and industry information	13. Geographic, product and industry information The table below sets forth revenues by geographic region, based on ship-to destinations. Americas consists of Canada, Mexico, and South America; EMEA consists of Europe, the Middle East, and Africa; and APAC consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia. Three months ended December 31, (in thousands) 2020 2019 United States $ 17,034 $ 9,827 EMEA 9,058 5,941 APAC 1,767 1,241 Americas 302 155 Total $ 28,161 $ 17,164 The table below sets forth revenues by products. Three months ended December 31, (in thousands) 2020 2019 Synthetic genes $ 8,874 $ 7,836 Oligo pools 1,510 1,242 DNA and Biopharma libraries 2,205 1,057 NGS tools 15,572 7,029 Total $ 28,161 $ 17,164 The table below sets forth revenues by industry. Three months ended December 31, (in thousands) 2020 2019 Industrial chemicals $ 7,132 $ 6,137 Academic research 4,901 4,951 Healthcare 15,976 5,835 Food/agricultural 152 241 Total $ 28,161 $ 17,164

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	3 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of presentation and use of estimates	Basis of presentation and use of estimates The accompanying unaudited condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K for the fiscal year ended September 30, 2020 (the Annual Report on Form 10-K) filed with the Securities and Exchange Commission on November 27, 2020. The condensed consolidated financial statements are unaudited and have been prepared on a basis consistent with that used to prepare the audited annual consolidated financial statements and include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. The condensed consolidated balance sheet at September 30, 2020 is derived from audited consolidated financial statements but does not include all disclosures required by GAAP. The operating results for the three months ended December 31, 2020 are not necessarily indicative of the results expected for the full year ending September 30, 2021 or any interim period. The presentation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company’s unaudited condensed consolidated financial statements include its wholly owned subsidiaries. All intercompany balances and accounts are eliminated in consolidation. The following table provides a reconciliation of the Company’s cash and cash equivalents and non-current portion of restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total cash, cash equivalents and restricted cash shown in the Company’s condensed consolidated statements of cash flows: (in thousands) December 2020 September 30, 2020 Cash and cash equivalents $ 348,789 $ 93,667 Restricted cash, non-current 1,530 579 Total cash, cash equivalents and restricted cash $ 350,319 $ 94,246
Significant accounting policies	Significant accounting policies There have been no material changes in the accounting policies from those disclosed in the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K.
Recent accounting pronouncements	Recent accounting pronouncements Recent adopted accounting pronouncements – Leases In February 2016, the Financial Accounting Standards Board (FASB) issued new lease accounting guidance in Accounting Standard Update (ASU) 2016-02, Leases, and in July 2018 issued ASU 2018-10, Codification Improvements to Topic 842, Leases, and ASU 2018-11, Leases (Topic 842): Targeted Improvements (the foregoing ASUs collectively referred to as “Topic 842”). Under the new guidance, lessees are required to recognize for all leases (with the exception of short-term leases) at the commencement date: (1) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and (2) a right-of-use asset, which is an asset that represents the lessee’s right to use or control the use of, a specified asset for the lease term. On October 1, 2019, the Company adopted Topic 842 using the modified retrospective approach. The adoption had a material effect on the condensed consolidated balance sheets but did not have a material effect on the condensed consolidated statements of operations and comprehensive loss. Prior period amounts were not adjusted and continue to be reported in accordance with the previous accounting under ASC 840, Leases. The Company elected the package of practical expedients permitted under the transition guidance which, among other things, allows carrying forward the historical classification of existing leases as of October 1, 2019. As a result of electing the transition guidance as described above, on October 1, 2019, the Company recorded operating lease right-of-use assets of $35.8 million, including the derecognition of deferred rent of $0.1 million and prepaid rent of $1.6 million, with the corresponding lease liabilities totaling $34.3 million. There was no material effect to the Company’s statements of operations and comprehensive loss upon adoption. Under Topic 842, the Company determines if an arrangement is a lease at inception primarily based on the determination of the party responsible for directing the use of an underlying asset within a contract. Operating lease right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of committed lease payments over the lease term. In determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date which includes significant assumptions made including the Company’s estimated credit rating, annual percentage yields from corporate debt financings of companies of similar size and credit rating over a loan term approximating the remaining term of each lease, and government bond yields for terms approximating the remaining term of each lease in countries where the leased assets are located. Certain leases include payments of operating expenses that are dependent and may be revised based on the landlord’s estimate, and these variable payments are therefore excluded from the lease payments used to determine the operating lease right-of-use asset and lease liability. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise any such options. Lease expense is recognized on a straight-line basis over the expected lease term. The Company elected to not apply the recognition requirements of Topic 842 to short-term leases with terms of 12 months or less which do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. For short-term leases, lease payments are recognized as operating expenses on a straight-line basis over the lease term. The Company elected to account for lease and non-lease components as a single lease component. Additional information and disclosures required by Topic 842 are contained in Note 6. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Subtopic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement In November 2018, the FASB is s Recently issued accounting pronouncement not yet adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes Income Taxes The ASU is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years, with early adoption permitted. The Company is currently assessing the impact of adoption on its disclosures.

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	3 Months Ended
	Dec. 31, 2020
Summary of Cash, Cash Equivalents and Restricted Cash	(in thousands) December 2020 September 30, 2020 Cash and cash equivalents $ 348,789 $ 93,667 Restricted cash, non-current 1,530 579 Total cash, cash equivalents and restricted cash $ 350,319 $ 94,246

Fair value measurement (Tables)

Fair value measurement (Tables)	3 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 and September 30, 2020 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value. December 31, 2020 (in thousands) Level 1 Level 2 Level 3 Fair value Assets Cash $ 40,108 $ — $ — $ 40,108 Money market funds 308,681 — — 308,681 Commercial paper — 132,867 — 132,867 U.S. government treasury bills 105,629 — — 105,629 Totals $ 454,418 $ 132,867 $ — $ 587,285 September 30, 2020 (in thousands) Level 1 Level 2 Level 3 Fair value Assets Cash $ 20,254 $ — $ — $ 20,254 Money market funds 73,413 — — 73,413 Commercial paper — 94,840 — 94,840 U.S. government treasury bills 101,495 — — 101,495 Totals $ 195,162 $ 94,840 $ — $ 290,002

Balance sheet components (Table

Balance sheet components (Tables)	3 Months Ended
	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Schedule Of Accounts Notes Loans And Financing Receivable	The Company’s accounts receivable, net balance consists of the following: (in thousands) December 31, 2020 September 30, 2020 Trade Receivables $ 23,639 $ 25,790 Other Receivables 2,260 951 Allowance for Doubtful Accounts (407 ) (365 ) Accounts Receivable, net $ 25,492 $ 26,376
Summary of Inventory	Inventory consist of the following: (in thousands) December 31, 2020 September 30, 2020 Raw Materials $ 9,940 $ 9,237 Work-in-process 1,701 2,021 Finished Goods 1,768 1,031 $ 13,409 $ 12,289

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	3 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets Balances	The intangible assets balances are presented below: December 31, 2020 (in thousands, except for years) Useful lives in years Gross carrying amount Accumulated amortization Net book value Developed Technology 6 $ 1,220 $ (964 ) $ 256 Tradenames & Trademarks 2 20 (20 ) — Total indefinite-lived intangible assets $ 1,240 $ (984 ) $ 256 September 30, 2020 (in thousands, except for years) Useful lives in years Gross carrying amount Accumulated amortization Net book value Developed Technology 6 $ 1,220 $ (913 ) $ 307 Tradenames & Trademarks 2 20 (20 ) — Total indefinite-lived intangible assets $ 1,240 $ (933 ) $ 307

Commitments and contingencies (

Commitments and contingencies (Tables)	3 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of Supplemental Balance Sheet Information Relating to Companies Operating Lease	Supplemental balance sheet information related to the Company’s operating lease as of December 31, 2020, was the following: (in thousands) December 31, 2020 Assets: Operating lease right-of-use-asset $ 32,330 Current liabilities: Current portion of operating lease liabilities $ 6,444 Noncurrent liabilities: Operating lease liabilities, net of current portion $ 23,681
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum lease payments under all non-cancelable operating leases that have commenced (in thousands) Operating leases Years ending September 30: Remainder of 2021 $ 4,850 2022 7,140 2023 6,761 2024 6,392 2025 6,433 Thereafter 4,906 Total minimum lease payments $ 36,482 Less: imputed interest (6,357 ) Total operating lease liabilities $ 30,125 Less: current portion (6,444 ) Operating lease liabilities, net of current portion $ 23,681

Stock-based compensation (Table

Stock-based compensation (Tables)	3 Months Ended
	Dec. 31, 2020
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Activity Under The Equity Incentive Plans	Activity under the equity incentive plans during the three months ended (In thousands, except per share data) Shares available Options outstanding Weighted average Weighted average remaining contractual term (years) Aggregate intrinsic value Outstanding at September 30, 2020 1,034 3,913 $ 24.35 8.1 $ 204,365 Stock options granted (33 ) 33 100.21 Stock options exercised — (348 ) 17.59 Stock options forfeited 29 (29 ) 31.32 Restricted stock units granted (289 ) — — Forfeiture of restricted stock units 9 — — Shares withheld for payment of taxes 24 — — Outstanding at Decem b 774 3,569 $ 24.99 7.9 $ 415,052 Vested or expected to vest 3,569 $ 24.99 7.9 $ 415,052 Vested and exercisable at December 31, 202 0 1,300 $ 14.99 7.0 $ 164,229
Total Stock-based Compensation Expense	Total stock-based compensation expense recognized was as follows: Three months ended December 31, (in thousands) 2020 2019 Cost of revenues $ 487 $ 360 Research and development 2,001 728 Selling, general and administrative 4,534 2,609 Total stock-based compensation $ 7,022 $ 3,697
Schedule of Nonvested Restricted Stock Units Activity	Activity with respect to the Company’s RSUs (in thousands, except per share data) Number of Shares Weighted average grant date fair value per share Weighted average remaining contractual term (years) Aggregate Intrinsic Value Outstanding at September 30, 2020 569 $ 32.96 3.2 $ 43,260 Restricted stock units granted 289 100.13 Restricted stock units vested (56 ) 24.86 Restricted stock units forfeited (9 ) 65.63 Outstanding at December 31, 2020 793 $ 57.67 3.3 $ 112,013 Expected to vest at December 31, 2020 793 $ 57.67 3.3 $ 112,013
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The number of shares reserved for issuance as at December 31, 2020 is as follows: (In thousands) Shares available Outstanding at September 30, 2020 179 Additional shares authorized 250 Shares issued during the period — Outstanding at December 31, 2020 429

Net loss per share attributab_2

Net loss per share attributable to common stockholders (Tables)	3 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Computation of the Company's Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders: Three months ended December 31, (in thousands, except per share data) 2020 2019 Numerator: Net loss attributable to common stockholders $ (32,900 ) $ (55,638 ) Denominator: Weighted average shares used in computing net loss per share, basic and diluted 46,000 32,976 Net loss per share attributable to common stockholders, basic and diluted $ (0.72 ) $ (1.69 )
Summary of Calculation of Diluted Net Loss Per Share	The potentially dilutive common shares that were excluded from the calculation of diluted net loss per share because their effect would have been anti- dilutive for the periods presented are as follows: Three months ended December 31, (in thousands) 2020 2019 Shares subject to options to purchase common stock 3,569 4,210 Shares subject to performance-based stock options 37 — Unvested restricted shares of common stock — 14 Unvested restricted stock unit s 793 566 Unvested shares of common stock issued upon early exercise of stock options 13 32 Shares subject to employee stock purchase plan 31 80 Shares subject to warrants to purchase common stock — 26 Total 4,443 4,928

Geographic, product and indus_2

Geographic, product and industry information (Tables)	3 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Summary of Revenue by Geographic Region	The table below sets forth revenues by geographic region, based on ship-to destinations. Americas consists of Canada, Mexico, and South America; EMEA consists of Europe, the Middle East, and Africa; and APAC consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia. Three months ended December 31, (in thousands) 2020 2019 United States $ 17,034 $ 9,827 EMEA 9,058 5,941 APAC 1,767 1,241 Americas 302 155 Total $ 28,161 $ 17,164
Summary of Revenue by Product	The table below sets forth revenues by products. Three months ended December 31, (in thousands) 2020 2019 Synthetic genes $ 8,874 $ 7,836 Oligo pools 1,510 1,242 DNA and Biopharma libraries 2,205 1,057 NGS tools 15,572 7,029 Total $ 28,161 $ 17,164
Summary of Revenue by Industry	The table below sets forth revenues by industry. Three months ended December 31, (in thousands) 2020 2019 Industrial chemicals $ 7,132 $ 6,137 Academic research 4,901 4,951 Healthcare 15,976 5,835 Food/agricultural 152 241 Total $ 28,161 $ 17,164

The company - Additional Inform

The company - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended						3 Months Ended
	Dec. 31, 2020	Jun. 30, 2020	Feb. 29, 2020	Jan. 31, 2020	May 31, 2019	Oct. 31, 2018	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2020
Accumulated deficit	$ (491,355)						$ (491,355)		$ (458,455)
IPO [Member]
Proceeds of underwritten public offering common stock					$ 84,300	$ 69,600
At The Market Offering [Member]
Proceeds of underwritten public offering common stock				$ 48,000				$ 48,000
Subsequent Public Offering [Member]
Proceeds of underwritten public offering common stock	$ 323,900	$ 107,400	$ 140,200				$ 323,900

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Sep. 30, 2020	Oct. 01, 2019
Operating lease right of use assets	$ 32,330	$ 33,699
Operating lease liabilities	$ 30,125
Accounting Standards Update 2018-11 [Member]
Operating lease right of use assets			$ 35,800
Operating lease deferred rent			100
Operating lease prepaid rent			1,600
Operating lease liabilities			$ 34,300

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	$ 348,789	$ 93,667
Restricted cash, non-current	1,530	579
Total cash, cash equivalents and restricted cash	$ 350,319	$ 94,246	$ 26,955	$ 47,398

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Sep. 30, 2020
Assets
Assets, Totals	$ 587,285	$ 290,002
Commercial Paper [Member]
Assets
Assets, Totals	132,867	94,840
US Government Treasury Bills [Member]
Assets
Assets, Totals	105,629	101,495
Cash [Member]
Assets
Assets, Totals	40,108	20,254
Money Market Funds [Member]
Assets
Assets, Totals	308,681	73,413
Fair Value, Inputs, Level 1 [Member]
Assets
Assets, Totals	454,418	195,162
Fair Value, Inputs, Level 1 [Member] | US Government Treasury Bills [Member]
Assets
Assets, Totals	105,629	101,495
Fair Value, Inputs, Level 1 [Member] | Cash [Member]
Assets
Assets, Totals	40,108	20,254
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Assets
Assets, Totals	308,681	73,413
Fair Value, Inputs, Level 2 [Member]
Assets
Assets, Totals	132,867	94,840
Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]
Assets
Assets, Totals	$ 132,867	$ 94,840

Balance sheet components - Sche

Balance sheet components - Schedule Of Accounts Notes Loans And Financing Receivable (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Sep. 30, 2020
Trade Receivables	$ 23,639	$ 25,790
Other Receivables	2,260	951
Allowance for Doubtful Accounts	(407)	(365)
Accounts Receivable, net	$ 25,492	$ 26,376

Balance sheet components - Summ

Balance sheet components - Summary of Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Sep. 30, 2020
Balance Sheet Related Disclosures [Abstract]
Raw Materials	$ 9,940	$ 9,237
Work-in-process	1,701	2,021
Finished Goods	1,768	1,031
Total inventories	$ 13,409	$ 12,289

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2020
Goodwill And Intangible Assets [Line Items]
Changes in carrying value of goodwill	$ 0		$ 0
Maximum [Member]
Goodwill And Intangible Assets [Line Items]
Total amortization expense related to intangible assets	$ 0.1	$ 0.1

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Summary of Intangible Assets Balances (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 1,240	$ 1,240
Accumulated amortization	(984)	(933)
Net book value	$ 256	$ 307
Developed Technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life in years	6 years	6 years
Gross carrying amount	$ 1,220	$ 1,220
Accumulated amortization	(964)	(913)
Net book value	$ 256	$ 307
Tradenames & Trademarks [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life in years	2 years	2 years
Gross carrying amount	$ 20	$ 20
Accumulated amortization	$ (20)	$ (20)

Commitments and contingencies -

Commitments and contingencies - Additional Information (Detail) $ in Thousands	3 Months Ended
	Dec. 31, 2020USD ($)ft²	Dec. 31, 2019USD ($)
Operating lease expense	$ 1,900	$ 2,000
Operating lease minimum lease payments	36,482
Operating lease payment	$ 1,700	$ 1,900
Lease weighted-average remaining lease term	5 years 3 months 10 days
Lease weighted average discount rate	6.99%
Wilsonville Oregon [Member] | Commercial Real Estate [Member]
Operating lease term	12 years
Operating lease minimum lease payments	$ 27,900
Operating lease base rent annual percentage increase	3.00%
Area of property subject to operating lease | ft²	110,995
Operating lease security deposit with the lessor	$ 1,000
Contingent liability letter of credit	1,000
Operating lease annual base rent	1,700
Tenant improvement allowance from lessor	$ 13,300
Wilsonville Oregon [Member] | Commercial Real Estate [Member] | Renewal Term One [Member]
Extension of Sub lease term	5 years
Wilsonville Oregon [Member] | Commercial Real Estate [Member] | Renewal Term Two [Member]
Extension of Sub lease term	5 years

Commitments and contingencies_2

Commitments and contingencies - Schedule of Supplemental Balance Sheet Information Relating to Companies Operating Lease (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Sep. 30, 2020
Assets:
Operating lease right-of-use-asset	$ 32,330	$ 33,699
Current liabilities:
Current portion of operating lease liabilities	6,444	6,409
Noncurrent liabilities:
Operating lease liabilities, net of current portion	$ 23,681	$ 24,837

Commitments and contingencies_3

Commitments and contingencies - Schedule Of Future Minimum Rental Payments For Operating Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
2021	$ 4,850
2022	7,140
2023	6,761
2024	6,392
2025	6,433
Thereafter	4,906
Total minimum lease payments	36,482
Less: imputed interest	(6,357)
Total operating lease liabilities	30,125
Less: current portion	(6,444)	$ (6,409)
Operating lease liabilities, net of current portion	$ 23,681	$ 24,837

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Raw materials purchased from related party investor	$ 1.1	$ 0.7
Description of related party transactions	During the three months ended December 31, 2020 and 2020, the Company purchased raw materials from a related party investor in the amount of $1.1 million and $0.7 million, respectively. Payable balances and cash receipts and receivable balances with the related party were immaterial as of December 31, 2020 and September 30, 2020.

Warrants - Additional Informati

Warrants - Additional Information (Detail) - $ / shares	Nov. 01, 2020	Oct. 01, 2020	Mar. 28, 2016	Dec. 22, 2015	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Net exercise of stock warrants		16,051
Number of shares underlying warrants	7,531	18,854
Exercise price per share	$ 21.24	$ 14.85
Common stock issued for cashless exercise	6,041	16,051
Class of warrants or rights outstanding					0	26,385
Warrants One [Member]
Class of Warrant or Right [Line Items]
Class of warrants or rights number of warrants issued during the period			7,531	18,854

Common stock - Additional info

Common stock - Additional information (Detail) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended				3 Months Ended
	Dec. 31, 2020	Jun. 30, 2020	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
At The Market Offering [Member]
Sale Of Stock Authorized Amount	$ 50				$ 50
Number of shares issued					2,239,680
Price per share	$ 22.32				$ 22.32
Proceeds of underwritten public offering common stock				$ 48		$ 48
Over-Allotment Option [Member]
Number of shares issued			696,428
Issuance of common stock, shares		454,545			409,090
Subsequent Public Offering [Member]
Issuance of common stock, shares		3,484,848	4,642,857		3,136,362
Shares issued, price per share	$ 110	$ 33	$ 28		$ 110
Proceeds of underwritten public offering common stock	$ 323.9	$ 107.4	$ 140.2		$ 323.9

Stock-based compensation - Addi

Stock-based compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Sep. 26, 2018	Dec. 31, 2020	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, stock options		$ 38.4
Unrecognized stock-based compensation expense, period for recognition		2 years 3 months 18 days
Weighted average grant date fair value of stock options granted		$ 63.28
2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Minimum annual increase in share reserved for issuance	999,900
Annual automatic Increase in share reserved for issuance	4.00%
2018 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares may be issued	5,856,505
2018 ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Minimum annual increase in share reserved for issuance	249,470
Annual automatic Increase in share reserved for issuance	1.00%
Aggregate number of common stock shares reserved for issuance	275,225	429,000	179,000
2018 ESPP [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of payroll deduction to purchase common stock	15.00%
2015 ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
ESPP eligible employee common stock purchase price ratio	85.00%
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation by share based payment arrangement equity instruments other than options non vested outstanding grant date fair value		$ 57.67	$ 32.96
Restricted Stock Units (RSUs) [Member] | 2018 ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, stock options		$ 43.8
Unrecognized stock-based compensation expense, period for recognition		3 years
Phantom Share Units (PSUs) [Member] | Revised Annual Equity Award Programme [Member] | Executive Officers and Senior Level Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation by share based payment arrangement instruments other than options expected to vest outstanding		245,913
Share based compensation by share based payment arrangement equity instruments other than options non vested outstanding grant date fair value		$ 44.72
Share based compensation by share based payment arrangement equity instruments other than options unrecognized compensation		$ 9.4
Unrecognized stock-based compensation expense, period for recognition		1 year 9 months 18 days
Phantom Share Units (PSUs) [Member] | Revised Annual Equity Award Programme [Member] | Minimum [Member] | Executive Officers and Senior Level Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting Rights Percentage		0.00%
Phantom Share Units (PSUs) [Member] | Revised Annual Equity Award Programme [Member] | Maximum [Member] | Executive Officers and Senior Level Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting Rights Percentage		150.00%

Stock-based compensation - Summ

Stock-based compensation - Summary of Shares Reserved For Issuance (Detail) - 2018 Employee Stock Purchase Plan [Member] shares in Thousands	3 Months Ended
	Dec. 31, 2020shares
Disclosure Of Employee Stock Purchase Plan [Line Items]
Outstanding at September 30, 2020	179
Additional shares authorized	250
Shares issued during the period	0
Outstanding at December 31, 2020	429

Stock-based compensation - Acti

Stock-based compensation - Activity Under The Equity Incentive Plans (Detail) - 2018 Equity Incentive Plan [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available, Outstanding Beginning Balance	1,034,000
Shares available, Stock options granted	(33,000)
Shares available, Stock options forfeited	29,000
Shares available, Restricted stock units granted	(289,000)
Shares available, Forfeiture of restricted common stock	9,000
Shares available, Shares withheld for payment of taxes	24,000
Shares available, Outstanding Ending Balance	774,000	1,034,000
Number of options, Outstanding beginning balance	3,913,000
Options outstanding, Stock options granted	33,000
Options outstanding, Stock options exercised	(348,000)
Options outstanding, Stock options forfeited	(29,000)
Number of options, Outstanding ending balance	3,569,000	3,913,000
Options outstanding, Vested or expected to vest	3,569,000
Options outstanding, Vested and exercisable	1,300,000
Weighted average exercise price per share, Outstanding Beginning Balance	$ 24.35
Weighted average exercise price per share, Stock options granted	100.21
Weighted average exercise price per share, Stock options exercised	17.59
Weighted average exercise price per share, Stock options forfeited	31.32
Weighted average exercise price per share, Outstanding Ending Balance	24.99	$ 24.35
Weighted average exercise price per share, Vested or expected to vest	24.99
Weighted average exercise price per share, Vested and exercisable	$ 14.99
Weighted average remaining contractual term, Outstanding	7 years 10 months 24 days	8 years 1 month 6 days
Weighted average remaining contractual term, Vested or expected to vest	7 years 10 months 24 days
Weighted average remaining contractual term,Vested and exercisable	7 years
Aggregate intrinsic value, Outstanding	$ 415,052	$ 204,365
Aggregate intrinsic value, Vested or expected to vest	415,052
Aggregate intrinsic value, Vested and exercisable	$ 164,229

Stock-based compensation - Sche

Stock-based compensation - Schedule of Nonvested Restricted Stock Units Activity (Detail) - Restricted Stock Units (RSUs) [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020
Nonvested Restricted Stock Units Activity [Line Items]
Number of shares, Outstanding Beginning Balance	569,000
Number of shares, granted	289,000
Number of shares, vested	(56,000)
Number of shares, forfeited	(9,000)
Number of shares, Outstanding Ending Balance	793,000	569,000
Expected to vest, Outstanding	793,000
Weighted average grant date fair value price per share, Outstanding Beginning Balance	$ 32.96
Weighted average grant date fair value price per share, granted	100.13
Weighted average grant date fair value price per share, vested	24.86
Weighted average grant date fair value price per share, forfeited	65.63
Weighted average grant date fair value price per share, Outstanding Ending Balance	57.67	$ 32.96
Weighted average grant date fair value price per share, Expected to vest	$ 57.67
Weighted average remaining contractual term, granted	3 years 3 months 18 days	3 years 2 months 12 days
Weighted average remaining contractual term, Expected to vest	3 years 3 months 18 days
Aggregate intrinsic value, Outstanding	$ 112,013	$ 43,260
Aggregate intrinsic value, Expected to vest	$ 112,013

Stock-based compensation - Tota

Stock-based compensation - Total Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 7,022	$ 3,697
Cost of Revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	487	360
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	2,001	728
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 4,534	$ 2,609

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Computation of the Company's Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Numerator:
Net loss attributable to common stockholders	$ (32,900)	$ (55,638)
Denominator:
Weighted average shares used in computing net loss per share, basic and diluted	46,000	32,976
Net loss per share attributable to common stockholders, basic and diluted	$ (0.72)	$ (1.69)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Summary of Calculation of Diluted Net Loss Per Share (Detail) - shares shares in Thousands	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	4,443	4,928
Options To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	3,569	4,210
Stock Options Based On Performance [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	37
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount		14
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	793	566
Early Exercise Of Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	13	32
Warrants To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	0	26
Employee Stock Purchase Plan [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	31	80

Geographic, Product and Indus_3

Geographic, Product and Industry Information - Summary of Revenue by Geographic Region (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Revenue	$ 28,161	$ 17,164
United States [Member]
Segment Reporting Information [Line Items]
Revenue	17,034	9,827
EMEA [Member]
Segment Reporting Information [Line Items]
Revenue	9,058	5,941
APAC [Member]
Segment Reporting Information [Line Items]
Revenue	1,767	1,241
Americas [Member]
Segment Reporting Information [Line Items]
Revenue	$ 302	$ 155

Geographic, Product and Indus_4

Geographic, Product and Industry Information - Summary of Revenue by Product (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Revenue	$ 28,161	$ 17,164
Synthetic Genes [Member]
Segment Reporting Information [Line Items]
Revenue	8,874	7,836
Oligo Pools [Member]
Segment Reporting Information [Line Items]
Revenue	1,510	1,242
DNA and Biopharma libraries [Member]
Segment Reporting Information [Line Items]
Revenue	2,205	1,057
NGS Tools [Member]
Segment Reporting Information [Line Items]
Revenue	$ 15,572	$ 7,029

Geographic, Product and Indus_5

Geographic, Product and Industry Information - Summary of Revenue by Industry (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Revenue	$ 28,161	$ 17,164
Industrial Chemicals [Member]
Segment Reporting Information [Line Items]
Revenue	7,132	6,137
Academic Research [Member]
Segment Reporting Information [Line Items]
Revenue	4,901	4,951
Health Care [Member]
Segment Reporting Information [Line Items]
Revenue	15,976	5,835
Food/agricultural [Member]
Segment Reporting Information [Line Items]
Revenue	$ 152	$ 241